The iPhenMap artificial intelligence tool integrated genetic, metabolic, protein, epigenetic, single-cell, and clinical data from 2,000 patient tumor samples to uncover hidden cellular mechanisms.

Overview Debates Related claims Topics Sources

UCLA investigators developed MAESTRO, an artificial intelligence platform using large language models to analyze scientific knowledge and identify drug combinations that overcome cancer treatment resistance.

In the Beth Israel trial, consenting patients will interact with MAI-DxO alongside standard medical care to compare its recommendations against decisions made by human doctors.

Microsoft plans to conduct real-world clinical testing of MAI-DxO with Beth Israel Deaconess Medical Center in Boston to evaluate patient triage in emergency department waiting rooms.

Pathos AI will apply its Foundry platform to Tempus AI's neurological dataset to track patient outcomes and speed research into Alzheimer's disease biology.

Bristol Myers Squibb gained non-exclusive strategic access to Pathos AI's Foundry platform across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.

Pathos AI's Foundry platform operates thousands of AI agents that calculate the probability of success for clinical assets by analyzing clinical data, genomics, biological specimen data, and market competition.

MAESTRO evaluates potential drug pairings, ranks promising candidates, and generates testable biological explanations without relying on vast amounts of experimental training data.

To identify drug candidates, UCLA researchers supplied MAESTRO with scientific data on prostate cancer biology, resistance mechanisms, and known drug actions.

An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London, developed an artificial intelligence tool called iPhenMap to create biological maps of tumors.

Bristol Myers Squibb agreed to make fixed payments totaling $137.5 million through 2031 under a Statement of Work with Tempus AI for oncology data and analytic services.

Pathos AI's proprietary software platform Foundry has access to approximately 200 petabytes of oncological data to generate and test hypotheses on disease biology.

Essex Partnership University NHS Foundation Trust spent a net total of £4.3 million on Oxevision installation, software fees, and staff training between 2020 and 2025.

Swedish researchers tested the Dermalyser AI smartphone app across 36 primary care centers from May to December 2022, evaluating 253 suspicious skin lesions in 228 patients.

Mass General Brigham radiation oncologist Dr. Raymond Mak stated that the AI facial tools aim to quantify patient physical reserve and frailty to support personalized treatment decisions.

The FAHR-FaceAge tool estimates a patient's biological age from a photo, while FAHR-FaceSurvival predicts cancer survival outcomes directly from a facial photograph.

Mass General Brigham researchers developed FAHR-Face, an artificial intelligence foundation model that powers two medical prediction tools called FAHR-FaceAge and FAHR-FaceSurvival.

Machine-learning antibody profiles differentiated individuals who later developed complicated Crohn's disease from non-complicated Crohn's disease up to approximately 10 years before diagnosis with an AUC value of 0.85.

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

The deployment of the AI triage device reduced routine dermatology follow-up appointments from 27% under standard teledermatology down to 12%.

Use of the AI medical device lowered patient biopsy rates to between 26% and 29%, compared to 43% under standard face-to-face dermatological care.